Key result
In patients with atrial fibrillation and previous stroke or TIA, NOACs did not reduce stroke compared to warfarin but lowered the risk of intracranial bleeding.
Why the study?
Do NOACs reduce ischemic stroke and intracranial bleeding compared to warfarin in patients with atrial fibrillation and prior stroke or TIA?
Meta-Analysis (n=14,527)
Double-blind and Open-label
Randomized
Yes
Do NOACs reduce ischemic stroke and intracranial bleeding compared to warfarin in patients with atrial fibrillation and prior stroke or TIA?
In patients with atrial fibrillation and prior stroke or TIA, NOACs are not superior to warfarin for preventing ischemic stroke but significantly reduce the risk of intracranial bleeding.
Answers are grounded in this paper and cite their sources.
NOACs match warfarin for stroke prevention while halving intracranial bleeding; confirms safety advantage in this secondary prevention population.
PURPOSE: Patients with Atrial Fibrillation (AF) and prior stroke are classified as high risk in all risk stratification schemes. A systematic review and meta-analysis was performed to compare the efficacy and safety of New Oral Anticoagulants (NOACs) to warfarin in patients with AF and previous stroke or transient ischemic attack (TIA). METHODS: Three randomized controlled trials (RCTs), including total 14527 patients, comparing NOACs (apixaban, dabigatran and rivaroxaban) with warfarin were included in the analysis. Primary efficacy endpoint was ischemic stroke, and primary safety endpoint was intracranial bleeding. Random-effects models were used to pool efficacy and safety data across RCTs. RevMan and Stata software were used for direct and indirect comparisons, respectively. RESULTS: In patients with AF and previous stroke or TIA, effects of NOACs were not statistically different from that of warfarin, in reduction of stroke (Odds Ratio [OR] 0.86, 95% confidence interval [CI] 0.73- 1.01), disabling and fatal stroke (OR 0.85, 95% CI 0.71-1.04), and all-cause mortality (OR 0.90, 95% CI 0.79 -1.02). Randomization to NOACs was associated with a significantly lower risk of intracranial bleeding (OR 0.42, 95% CI 0.25-0.70). There were no major differences in efficacy between apixaban, dabigatran (110 mg BID and 150 mg BID) and rivaroxaban. Major bleeding was significantly lower with apixaban and dabigatran (110 mg BID) compared with dabigatran (150 mg BID) and rivaroxaban. CONCLUSION: NOACs may not be more effective than warfarin in the secondary prevention of ischemic stroke in patients with a prior history of cerebrovascular ischemia, but have a lower risk of intracranial bleeding.
No takes yet. Share an insight, caveat, or question.
Sardar et al. (2013) conducted a meta-analysis in Atrial Fibrillation with previous stroke or TIA (n=14,527). New Oral Anticoagulants (NOACs: apixaban, dabigatran, rivaroxaban) vs. Warfarin was evaluated on Ischemic stroke (OR 0.86, 95% CI 0.73-1.01, p=not statistically different). In patients with atrial fibrillation and previous stroke or TIA, NOACs did not reduce stroke compared to warfarin but lowered the risk of intracranial bleeding.
Synapse has enriched 10 related papers. Consider them for comparative context: